BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
Protester climbs on to balcony of Iranian embassy in London- Step by step instructions to Protect Your Speculations with Cd Rates
- Artemis 2 moon astronauts will try to recreate Apollo 8's historic 'Earthrise' photo during April 6 flyby
- My prescription costs what?! Pharmacists offer tips that could reduce your out-of-pocket drug costs
- New study measures titanium in Apollo rock to uncover Moon’s early chemistry
- New nesting beach for birds at RSPB reserve
- Ten Awesome Authentic Realities That Will Leave You Interested
- ‘Trip of suffering’: Gaza evacuee details 24-hour journey to South Africa
- Second doctor in Matthew Perry overdose case sentenced to home confinement
